3D rendering of purple cancer cells with yellow antibodies bound to blue surface receptors, red laser beam visible upper right, representing photoimmunotherapy targeting in peritoneal cancer research.
Amanda Moore Avatar

Research in photoimmunotherapy offers a promising path for patients whose tumors no longer respond to standard chemotherapy. You can read the original research here: “Inhibition of P-glycoprotein using photoimmunotherapy in peritoneal metastasis mouse model”

This is way too technical for me, but I did my best to make this “patient friendly”. Everyone already knows that surgery and chemotherapy do not always work the way they are supposed to. Tumors come back. Drugs stop working. Oncologists call this chemoresistance, and it is one of the most stubborn obstacles in treating cancers that spread to the peritoneum.

A 2026 study published in Photochemistry and Photobiology describes a technique that impaired one of the key mechanisms behind chemotherapy resistance in a mouse model of peritoneal cancer. The research used chemoresistant ovarian cancer cells, not appendiceal cancer cells, so it does not directly answer questions about appendix cancer. But it targets a resistance mechanism, P-glycoprotein, that may also matter in other cancers that spread through the peritoneum. Here is what the study found and why it may matter to this community.

Why Chemotherapy Stops Working

Cancer cells are, unfortunately, adaptive. Over time and repeated treatment, many develop the ability to recognize chemotherapy drugs and expel them before they can cause damage. One protein responsible for this is called P-glycoprotein, or P-gp. Think of it as a bouncer built into the wall of a cancer cell that pumps drugs back out the moment they enter.

P-gp is a problem across many cancer types, but it has been studied especially in ovarian cancer and peritoneal disease more broadly. In advanced ovarian cancer, recurrence is common, and 80 to 90 percent of recurrent cases are chemoresistant. P-gp directly effluxes taxanes such as Paclitaxel and Docetaxel, as well as Mitomycin C, drugs used in peritoneal cancer treatment, including intraperitoneal chemotherapy approaches. P-gp can also contribute to resistance to drugs like Cisplatin by interfering with apoptosis signaling.

Researchers have tried for decades to block P-gp using small molecule drugs. Those efforts have largely failed in clinical trials because the inhibitors caused too much toxicity when given systemically, or they did not concentrate where they were needed.

What is P-glycoprotein?
P-glycoprotein (P-gp) is a protein pump embedded in cancer cell membranes. Whenchemotherapy drugs enter the cell, P-gp actively pushes them back out, loweringthe intracellular drug concentration and making treatment less effective. It is awell-known driver of multidrug resistance in several cancers, especially ovariancancer, and may also contribute in other peritoneal malignancies.

What the Researchers Tried Instead

The University of Maryland team took a different approach. Rather than using a systemic drug to inhibit P-gp, they used light.

The technique is called photoimmunotherapy, or PIT. It works by attaching a light-sensitive molecule called a photosensitizer to an antibody that targets a receptor commonly overexpressed on cancer cells. In this study, the antibody was cetuximab, which targets a receptor called EGFR. Once the antibody-photosensitizer complex, called a photoimmunoconjugate or PIC, binds to the cancer cell, a laser at a specific wavelength activates it.

The key innovation here is that the researchers used a deliberately low, sub-therapeutic light dose. They were not trying to kill the tumor cells. They were trying to impair their function, specifically the function of P-gp, without causing the kind of cell death that would confound the results. Once the PIC binds to the cancer cell, laser activation generates photochemical damage, including singlet oxygen, that disrupts cellular function.

What They Found

The experiment used chemoresistant ovarian cancer cells that heavily overexpress P-gp. These cells were implanted into the peritoneal cavity of mice to create a model of peritoneal carcinomatosis. Twenty days later, the PIC was injected intraperitoneally, followed 24 hours later by laser light delivered into the abdominal cavity through a fiber inserted via a small catheter.

To measure whether P-gp was still functioning, the researchers exposed harvested tumor cells to a fluorescent dye called Rhodamine 123, which is a known P-gp substrate. Cells with active P-gp pump the dye back out. Cells with impaired P-gp retain it. The result: cells from PIT-treated mice retained 2.6 times more of the dye than cells from untreated mice. P-gp was still present in the cells, but its function appeared to be significantly impaired.

The P-gp inhibition was still measurable 24 hours after light activation. That matters clinically because it creates a window during which chemotherapy could be delivered and accumulate inside tumor cells before the pump recovers. A 24-hour window of reduced P-gp activity could, in theory, improve drug uptake, although that still needs to be tested directly in combination-treatment studies.

What the Numbers Mean
2.6-fold increase in drug retention inside treated cancer cellsP-gp inhibition detectable 24 hours after light activation. No reduction in tumor burden at this sub-therapeutic dose (by design). No significant change in mouse body weight or health markers. P-gp protein levels unchanged, confirming the pump was impaired, not destroyed

How This Connects to Appendiceal Cancer

This study did not use appendiceal cancer cells, and that distinction matters. The researchers used ovarian cancer cells chosen specifically because they over express P-gp and EGFR. Whether appendiceal tumors express EGFR at levels sufficient for cetuximab-based targeting is not addressed by this paper, and the authors note that targeted delivery depends on tumor biology, and alternative antibody targets may be needed in other settings.

That said, the resistance mechanism itself, P-gp-mediated drug efflux, may also be relevant in appendiceal cancer and other cancers that spread through the peritoneum. If PIT-based P-gp inhibition proves effective in human peritoneal disease, it would be a platform technology that researchers could potentially adapt across tumor types, using different antibody targets for different cancer cell profiles.

There is also a practical fit with the existing surgical workflow. The study authors propose that PIT could potentially be integrated into cytoreductive surgery. The PIC would be administered intraperitoneally before the procedure, and light would be delivered at the end of the operation using a fiber or balloon device. At the doses used, the entire light treatment takes roughly 11 minutes across four abdominal quadrants. In principle, HIPEC or other chemotherapy could then be timed to fall within the observed inhibition window, though this sequencing has not yet been tested.

Where the Research Goes from Here

This is a proof-of-concept study in mice. The next steps would involve testing PIT in combination with actual chemotherapy to confirm the P-gp inhibition translates into improved drug efficacy and tumor reduction. Researchers would also need to determine how long the inhibitory effect lasts and whether the technique works at higher, cytotoxic light doses where tumor killing and P-gp modulation happen simultaneously.

For the approach to reach appendiceal cancer patients specifically, researchers would need to characterize EGFR expression across appendiceal tumor subtypes and potentially explore alternative antibody targets for patients whose tumors do not express EGFR at meaningful levels.

None of this is imminent. But the core finding, that a targeted light-based therapy can impair a major drug resistance mechanism in a living model of peritoneal cancer, is a legitimate step forward.

Questions to Ask Your Care Team
– Is P-glycoprotein expression or multidrug resistance relevant to my tumor type?
– Have my tumors shown signs of resistance to taxanes, mitomycin C, or platinum agents?
– Are there clinical trials exploring ways to sensitize peritoneal tumors to chemotherapy before or during HIPEC?
– Is EGFR expression measured as part of my molecular profiling?
– What is known about the mechanisms behind my tumor’s chemoresistance?

Glossary

P-glycoprotein (P-gp): A protein pump in cancer cell membranes that actively expels chemotherapy drugs, reducing their effectiveness. Also called ABCB1 or MDR1.

Photoimmunotherapy (PIT): A treatment that combines a light-sensitive molecule with a cancer-targeting antibody. When activated by laser light, it disrupts cancer cell function.

Photoimmunoconjugate (PIC): The drug-antibody compound used in PIT. In this study, the photosensitizer BPD was attached to cetuximab.

EGFR: Epidermal growth factor receptor, a protein overexpressed on many cancer cells and used here as the antibody target.

Peritoneal carcinomatosis: Cancer spread to the peritoneum, the lining of the abdominal cavity. Common in advanced appendiceal, ovarian, and colorectal cancers.

CRS/HIPEC: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, the primary treatment approach for peritoneal metastasis.

Rhodamine 123 (Rh123): A fluorescent dye used as a tracer to measure P-gp activity. Cells with active P-gp pump it out; cells with impaired P-gp retain it.

Source

Moore KA, Schnoor B, McNaughton KL, et al. Inhibition of P-glycoprotein using photoimmunotherapy in peritoneal metastasis mouse model. Photochemistry and Photobiology. 2026. doi:10.1111/php.70075

This post is for informational purposes only and does not constitute medical advice. Please consult your oncology team before making any treatment decisions, but do share this and ALL research that may relate to your cancer to your medical team.

0 0

Share it!

Stay informed about the latest research and patient stories.

Posted in , ,

Leave a Reply